Collplant Holdings (CLGN) Price & Analysis

Compare

175 Followers

CLGN Stock Chart & Stats

$1.51

-$0.10(-2.34%)

At close: Jan 08 4:00 PM EST

$1.51

-$0.10(-2.34%)

Day’s Range― - ―

52-Week Range$1.30 - $4.98

Previous CloseN/A

Volume800.00

Average Volume (3M)29.18K

Market Cap

$19.20M

Enterprise Value$28.62M

Total Cash (Recent Filing)$8.55M

Total Debt (Recent Filing)$2.94M

Price to Earnings (P/E)―

Beta0.43

Next Earnings

Apr 02, 2026

EPS Estimate

-0.07

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.27

Shares Outstanding12,716,014

10 Day Avg. Volume15,198

30 Day Avg. Volume29,183

Financial Highlights & Ratios

PEG Ratio-0.02

Price to Book (P/B)3.06

Price to Sales (P/S)80.07

P/FCF Ratio-2.83

Enterprise Value/Market Cap1.49

Enterprise Value/Revenue11.56

Enterprise Value/Gross Profit46.01

Enterprise Value/Ebitda-2.59

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

PartnershipsCollPlant continues to progress the clinical development of its dermal and soft-tissue filler program in collaboration with AbbVie.

Product DevelopmentEncouraging initial breast implant data shows signs of implant integration and rapid growth of native tissue, supporting potential future commercialization.

Bears Say

Financial PerformanceThe company reported total revenues of $0.25M, compared to the consensus estimate of $0.69M.

Collplant Holdings News

CollPlant files $100M mixed securities shelf

16:19 EST CollPlant (CLGN) files $100M mixed securities shelf Published first on TheFly – the ultimate source for...

5d ago

CLGN

CollPlant Shareholders Approve All Proposals at December 31, 2025 General Meeting

An update from Collplant Holdings ( ($CLGN) ) is now available. On December 31, 2025, CollPlant Biotechnologies Ltd....

14d ago

CLGN

CollPlant Biotechnologies Reports Q3 2025 Financial Results

CollPlant Biotechnologies Ltd. ( ($CLGN) ) has released its Q3 earnings. Here is a breakdown of the information...

2M ago

CLGN

CollPlant Biotechnologies Announces Annual and Extraordinary General Meeting for December 2025

The latest update is out from Collplant Holdings ( ($CLGN) ). On November 26, 2025, CollPlant Biotechnologies Ltd....

2M ago

CLGN

CollPlant Biotechnologies Expands North American Operations and Reports Q3 2025 Results

Collplant Holdings ( ($CLGN) ) just unveiled an announcement. CollPlant Biotechnologies reported its third-quarter financial results for 2025,...

2M ago

CLGN

CollPlant to reduce workforce by 25%

Yehiel Tal, CollPlant’s (CLGN) CEO, commented, “In 2026, CollPlant will prioritize its collaboration with AbbVie (ABBV) and continue...

2M ago

ABBV

CLGN

CollPlant reports Q3 non-GAAP EPS (25c) vs. (33c) last year

Reports Q3 revenue $77,000 vs. $4,000 last year. Yehiel Tal, CollPlant’s (CLGN) CEO, remarked, “CollPlant continued to advance...

2M ago

CLGN

CLGN Upcoming Earnings Report: What to Expect?

CollPlant Biotechnologies Ltd. (CLGN) is scheduled to report 3rd quarter earnings on 11/26/2025. Regarding Q3 estimates, Wall Street...

2M ago

CLGN

CollPlant Expands rhCollagen Distribution in North America

Collplant Holdings ( ($CLGN) ) has issued an announcement. On October 27, 2025, CollPlant Biotechnologies announced the expansion...

3M ago

CLGN

CollPlant expands rhCollagen capabilities in U.S., Canada

CollPlant (CLGN) Biotechnologies announced the expansion of its distribution footprint into North America through a new partnership with...

3M ago

CLGN

CollPlant’s BioInk Outperforms Matrigel in Technion Study

Collplant Holdings ( ($CLGN) ) has issued an announcement. On October 20, 2025, CollPlant Biotechnologies announced positive results...

3M ago

CLGN

CollPlant’s Collink.3D shows strong performance vs. Matrigel in study

CollPlant Biotechnologies (CLGN) announced positive results from a head-to-head comparative study of its rhCollagen-based bioink, Collink.3D, and Matrigel,...

3M ago

GLW

CLGN

CollPlant and Mayo Clinic Unveil Humanized 3D Bioprinted Skin Model

An update from Collplant Holdings ( ($CLGN) ) is now available. On October 16, 2025, CollPlant Biotechnologies announced...

3M ago

CLGN

Morning News Wrap-Up: Tuesday’s Biggest Stock Market Stories!

Traders will find all of the latest earnings reports, analyst updates, and government shutdown updates in today’s daily...

4M ago

CLGN FAQ

What was Collplant Holdings’s price range in the past 12 months?

Collplant Holdings lowest stock price was $1.30 and its highest was $4.98 in the past 12 months.

What is Collplant Holdings’s market cap?

Collplant Holdings’s market cap is $19.20M.

When is Collplant Holdings’s upcoming earnings report date?

Collplant Holdings’s upcoming earnings report date is Apr 02, 2026 which is in 78 days.

How were Collplant Holdings’s earnings last quarter?

Collplant Holdings released its earnings results on Nov 26, 2025. The company reported -$0.27 earnings per share for the quarter, missing the consensus estimate of $0.155 by -$0.425.

Is Collplant Holdings overvalued?

According to Wall Street analysts Collplant Holdings’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Collplant Holdings pay dividends?

Collplant Holdings does not currently pay dividends.

What is Collplant Holdings’s EPS estimate?

Collplant Holdings’s EPS estimate is -0.07.

How many shares outstanding does Collplant Holdings have?

Collplant Holdings has 12,716,014 shares outstanding.

What happened to Collplant Holdings’s price movement after its last earnings report?

Collplant Holdings reported an EPS of -$0.27 in its last earnings report, missing expectations of $0.155. Following the earnings report the stock price went down -0.446%.

Which hedge fund is a major shareholder of Collplant Holdings?

Currently, no hedge funds are holding shares in CLGN

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Collplant Holdings

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; injectable implants to promote breast tissue regeneration; 3D bioprinted regenerative soft tissue matrix; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. It has collaboration agreements with 3D Systems Corporation; CellInk, a BICO Group company; Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; Israel's Technion Institute of Technology; AbbVie; and STEMCELL. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.